Jane E. Mendez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jane E. Mendez has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Antonio de Las Morenas
Boston University School of Medicine
3 shared publications Maureen Kavanah
Department of Surgery, Boston University Medical Center, Boston, Massachusetts
3 shared publicationsMichael D. Stone
Division of Surgical Oncology, Boston University School of Medicine, Boston, MA, USA
3 shared publications- Anusri Tripathi
Department of Biochemistry and Medical Biotechnology Calcutta School of Tropical Medicine Kolkata West Bengal India
2 shared publications - Carol L. Rosenberg
Department of Pathology, Boston Medical Center and Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA
2 shared publications Chialin King
Department of Medicine, Boston University Medical Center, Boston, Massachusetts
2 shared publications
Latest Publications
- 20 September 2014
- Published by Springer Nature
- p. 141-161
BRCA1 and BRCA2 in Breast Cancer and Ovarian Cancer
- 20 September 2014
- Published by Springer Nature
- p. 141-161
BRCA1 and BRCA2 in Breast Cancer and Ovarian Cancer
- Open Access
- 2 March 2010
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (8) , 1284-1293
Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile
We hypothesised that gene expression in histologically normal (HN) epithelium (NlEpi) would differ between breast cancer patients and usual-risk controls undergoing reduction mammoplasty (RM), and that gene expression in NlEpi from cancer-free prophylactic mastectomy (PM) samples from high-risk women would resemble HN gene expression. We analysed gene expression in 73 NlEpi samples microdissected from frozen tissue. In 42 samples, we used microarrays to compare gene expression between 18 RM patients and 18 age-matched HN (9 oestrogen receptor (ER)+, 9 ER−) and 6 PM patients. Data were analysed using a Bayesian approach (BADGE), and validated with quantitative real-time PCR (qPCR) in 31 independent NlEpi samples from 8 RM, 17 HN, and 6 PM patients. A total of 98 probe sets (86 genes) were differentially expressed between RM and HN samples. Performing hierarchical analysis with these 98 probe sets, PM and HN samples clustered together, away from RM samples. qPCR validation of independent samples was high (84%) and uniform in RM compared with HN patients, and lower (58%), but more heterogeneous, in RM compared with PM patients. The 86 genes were implicated in many processes including transcription and the MAPK pathway. Gene expression differs between the NlEpi of breast cancer cases and controls. The profile of cancer cases can be discerned in high-risk NlEpi from cancer-free breasts. This suggests that the profile is not an effect of the tumour, but may mark increased risk and reveal the earliest genomic changes of breast cancer.
- 2 March 2010
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (8) , 1284-1293
Open AccessGene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile
We hypothesised that gene expression in histologically normal (HN) epithelium (NlEpi) would differ between breast cancer patients and usual-risk controls undergoing reduction mammoplasty (RM), and that gene expression in NlEpi from cancer-free prophylactic mastectomy (PM) samples from high-risk women would resemble HN gene expression. We analysed gene expression in 73 NlEpi samples microdissected from frozen tissue. In 42 samples, we used microarrays to compare gene expression between 18 RM patients and 18 age-matched HN (9 oestrogen receptor (ER)+, 9 ER−) and 6 PM patients. Data were analysed using a Bayesian approach (BADGE), and validated with quantitative real-time PCR (qPCR) in 31 independent NlEpi samples from 8 RM, 17 HN, and 6 PM patients. A total of 98 probe sets (86 genes) were differentially expressed between RM and HN samples. Performing hierarchical analysis with these 98 probe sets, PM and HN samples clustered together, away from RM samples. qPCR validation of independent samples was high (84%) and uniform in RM compared with HN patients, and lower (58%), but more heterogeneous, in RM compared with PM patients. The 86 genes were implicated in many processes including transcription and the MAPK pathway. Gene expression differs between the NlEpi of breast cancer cases and controls. The profile of cancer cases can be discerned in high-risk NlEpi from cancer-free breasts. This suggests that the profile is not an effect of the tumour, but may mark increased risk and reveal the earliest genomic changes of breast cancer.
- 1 October 2009
- Published by Elsevier in The American Journal of Surgery
- Vol. 198 (4) , 526-528
Promoters and barriers to mammography screening in multiethnic inner city patients
- 1 October 2009
- Published by Elsevier in The American Journal of Surgery
- Vol. 198 (4) , 526-528
Promoters and barriers to mammography screening in multiethnic inner city patients
- 1 September 2009
- Published by Elsevier in The American Journal of Pathology
- Vol. 175 (3) , 1292-1302
Early Dysregulation of Cell Adhesion and Extracellular Matrix Pathways in Breast Cancer Progression
- 1 September 2009
- Published by Elsevier in The American Journal of Pathology
- Vol. 175 (3) , 1292-1302
Early Dysregulation of Cell Adhesion and Extracellular Matrix Pathways in Breast Cancer Progression
- 25 January 2008
- Published by Wiley in International Journal of Cancer
- Vol. 122 (7) , 1557-1566
Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients
Normal‐appearing epithelium of cancer patients can harbor occult genetic abnormalities. Data comprehensively comparing gene expression between histologically normal breast epithelium of breast cancer patients and cancer‐free controls are limited. The present study compares global gene expression between these groups. We performed microarrays using RNA from microdissected histologically normal terminal ductal‐lobular units (TDLU) from 2 groups: (i) cancer normal (CN) (TDLUs adjacent to untreated ER+ breast cancers (n = 14)) and (ii) reduction mammoplasty (RM) (TDLUs of age‐matched women without breast disease (n = 15)). Cyber‐T identified differentially expressed genes. Quantitative RT‐PCR (qRT‐PCR), immunohistochemistry (IHC), and comparison to independent microarray data including 6 carcinomas in situ (CIS), validated the results. Gene ontology (GO), UniProt and published literature evaluated gene function. About 127 probesets, corresponding to 105 genes, were differentially expressed between CN and RM (p < 0.0009, corresponding to FDR vs. RM. Two‐thirds of the 105 genes were implicated previously in carcinogenesis. Overrepresented functional groups included transcription, G‐protein coupled and chemokine receptor activity, the MAPK cascade and immediate early genes. Most genes in these categories were under‐expressed in CN vs. RM. We conclude that global gene expression abnormalities exist in normal epithelium of breast cancer patients and are also present in early cancers. Thus, cancer‐related pathways may be perturbed in normal epithelium. These abnormalities could be markers of disease risk, occult disease, or the tissue's response to an existing tumor.
- 25 January 2008
- Published by Wiley in International Journal of Cancer
- Vol. 122 (7) , 1557-1566
Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients
Normal‐appearing epithelium of cancer patients can harbor occult genetic abnormalities. Data comprehensively comparing gene expression between histologically normal breast epithelium of breast cancer patients and cancer‐free controls are limited. The present study compares global gene expression between these groups. We performed microarrays using RNA from microdissected histologically normal terminal ductal‐lobular units (TDLU) from 2 groups: (i) cancer normal (CN) (TDLUs adjacent to untreated ER+ breast cancers (n = 14)) and (ii) reduction mammoplasty (RM) (TDLUs of age‐matched women without breast disease (n = 15)). Cyber‐T identified differentially expressed genes. Quantitative RT‐PCR (qRT‐PCR), immunohistochemistry (IHC), and comparison to independent microarray data including 6 carcinomas in situ (CIS), validated the results. Gene ontology (GO), UniProt and published literature evaluated gene function. About 127 probesets, corresponding to 105 genes, were differentially expressed between CN and RM (p < 0.0009, corresponding to FDR vs. RM. Two‐thirds of the 105 genes were implicated previously in carcinogenesis. Overrepresented functional groups included transcription, G‐protein coupled and chemokine receptor activity, the MAPK cascade and immediate early genes. Most genes in these categories were under‐expressed in CN vs. RM. We conclude that global gene expression abnormalities exist in normal epithelium of breast cancer patients and are also present in early cancers. Thus, cancer‐related pathways may be perturbed in normal epithelium. These abnormalities could be markers of disease risk, occult disease, or the tissue's response to an existing tumor.
- 31 October 2007
- Published by Elsevier in The American Journal of Surgery
- Vol. 194 (4) , 482-487
Positive impact of a breast-health triaging system on breast-care access and physician satisfaction
- 31 October 2007
- Published by Elsevier in The American Journal of Surgery
- Vol. 194 (4) , 482-487
Positive impact of a breast-health triaging system on breast-care access and physician satisfaction
- 31 October 2006
- Published by Elsevier in The American Journal of Surgery
- Vol. 192 (4) , 538-540
Influence of breast cancer margin assessment method on the rates of positive margins and residual carcinoma
- 31 October 2006
- Published by Elsevier in The American Journal of Surgery
- Vol. 192 (4) , 538-540
Influence of breast cancer margin assessment method on the rates of positive margins and residual carcinoma
- 27 December 2004
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 12 (1) , 24-28
Can Sentinel Lymph Node Biopsy Be Omitted in Patients With Favorable Breast Cancer Histology?
The widespread use of sentinel lymph node biopsy (SLNB) to replace axillary dissection has broadened the indications for axillary staging in breast cancer. Recent studies have demonstrated a finite risk of lymphedema and sensory morbidity associated with SLNB. We undertook this study to determine whether SLNB could be omitted in clinically node-negative patients with favorable-histology breast cancer. We conducted a retrospective review of a prospective database of SLNBs performed at Memorial Sloan-Kettering Cancer Center from 1996 to 2003 to determine the incidence of lymph node metastases by histological subtype. For the favorable subtypes, the patient’s age, tumor size, estrogen receptor status, lymphovascular invasion, nuclear grade, and histological grade were compared by nodal status to determine their predictive value. A total of 196 cases with favorable breast cancer subtypes were identified with a 4.1% (8 of 196) sentinel lymph node (SLN) positivity rate. Each of the histological subtypes included patients with positive SLNs, with the exception of adenoid cystic (n = 4) and secretory (n = 1) breast carcinoma, which were quite rare in our series. When compared by nodal status, the patient’s age, tumor size, estrogen receptor status, lymphovascular invasion, nuclear grade, and histological grade failed to predict those with positive SLNs. Patients with favorable breast cancer histology have a small risk of axillary SLN metastases. The use of SLNB in these patients should be individualized, taking into consideration the small incidence of axillary metastases and the risks and benefits associated with the SLN procedure.
- 27 December 2004
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 12 (1) , 24-28
Can Sentinel Lymph Node Biopsy Be Omitted in Patients With Favorable Breast Cancer Histology?
The widespread use of sentinel lymph node biopsy (SLNB) to replace axillary dissection has broadened the indications for axillary staging in breast cancer. Recent studies have demonstrated a finite risk of lymphedema and sensory morbidity associated with SLNB. We undertook this study to determine whether SLNB could be omitted in clinically node-negative patients with favorable-histology breast cancer. We conducted a retrospective review of a prospective database of SLNBs performed at Memorial Sloan-Kettering Cancer Center from 1996 to 2003 to determine the incidence of lymph node metastases by histological subtype. For the favorable subtypes, the patient’s age, tumor size, estrogen receptor status, lymphovascular invasion, nuclear grade, and histological grade were compared by nodal status to determine their predictive value. A total of 196 cases with favorable breast cancer subtypes were identified with a 4.1% (8 of 196) sentinel lymph node (SLN) positivity rate. Each of the histological subtypes included patients with positive SLNs, with the exception of adenoid cystic (n = 4) and secretory (n = 1) breast carcinoma, which were quite rare in our series. When compared by nodal status, the patient’s age, tumor size, estrogen receptor status, lymphovascular invasion, nuclear grade, and histological grade failed to predict those with positive SLNs. Patients with favorable breast cancer histology have a small risk of axillary SLN metastases. The use of SLNB in these patients should be individualized, taking into consideration the small incidence of axillary metastases and the risks and benefits associated with the SLN procedure.
- 1 August 2004
- Published by SAGE Publications in The American Surgeon™
- Vol. 70 (8) , 720-725
Primary Lymphoma of the Breast: A Case of Marginal Zone B-Cell Lymphoma
A case of primary marginal zone B-cell lymphoma in an elderly female patient is presented. Primary breast lymphomas are rare, comprising less than 1 per cent of all breast malignancies. These tumors have no clinical, pathologic, or radiologic pathognomonic features to distinguish them from breast adenocarcinoma. The diagnosis is usually made with an excisional biopsy, and more extensive surgery should be avoided. Delivery of radiation therapy and chemotherapy is tailored according to the histologic grade, stage of disease, and overall patient condition. This report summarizes the current knowledge reflected in the literature.
- 1 August 2004
- Published by SAGE Publications in The American Surgeon™
- Vol. 70 (8) , 720-725
Primary Lymphoma of the Breast: A Case of Marginal Zone B-Cell Lymphoma
A case of primary marginal zone B-cell lymphoma in an elderly female patient is presented. Primary breast lymphomas are rare, comprising less than 1 per cent of all breast malignancies. These tumors have no clinical, pathologic, or radiologic pathognomonic features to distinguish them from breast adenocarcinoma. The diagnosis is usually made with an excisional biopsy, and more extensive surgery should be avoided. Delivery of radiation therapy and chemotherapy is tailored according to the histologic grade, stage of disease, and overall patient condition. This report summarizes the current knowledge reflected in the literature.